Read next
GLP-1 Supply Shortages Spur Expanded Manufacturing Capacity
Pharmaceutical manufacturers are directing capital expenditure toward sterile injectable production to meet soaring demand for metabolic therapies.
Targeted RNA Therapeutics Show Promise in Oncology Trials
Phase II clinical trial data demonstrates precise protein suppression in solid tumors with minimal off-target toxicity.
Targeted RNA Therapeutics Target Rare Metabolic Disorders
Clinical trials report significant expression reductions in disease-causing proteins, opening pathways for precise gene-silencing drugs.
How Much Sleep You Actually Need
Eight hours is an average, not a requirement. Individual need varies and consistency matters as much as duration.
GLP-1 Class Drugs Reshape Pharmaceutical Pipelines and MedTech Valuations
The rapid adoption of metabolic therapies is altering long-term forecasts for cardiovascular, orthopedic, and medical device sectors.
Clinical Trials Accelerate Integration of Synthetic Control Arms
Pharmaceutical firms are leveraging historical patient datasets to construct synthetic control arms, significantly reducing phase II clinical trial…